国药集团，严正声明！

Core Viewpoint - China National Pharmaceutical Group (Sinopharm Group) has issued a statement regarding its relationship with China Medicine Holdings Co., Ltd. (Medicine Holdings), emphasizing that it has no current equity or control relationship with Medicine Holdings after transferring its 25% stake [3][4]. Group 1 - Sinopharm Group's subsidiary, China Traditional Chinese Medicine Co., Ltd. (Sinopharm TCM), has publicly announced the transfer of its 25% stake in Medicine Holdings to Shanghai Tianyue Tenghua Trading Service Co., Ltd. [3] - Following the completion of this transfer, Sinopharm TCM will no longer hold any equity in Medicine Holdings, and there will be no equity or control relationship between Sinopharm Group, Sinopharm TCM, and Medicine Holdings [4]. - Sinopharm Group has never authorized Medicine Holdings or its subsidiaries to use its trademarks or engage in activities under its name, and it does not take responsibility for any actions taken by Medicine Holdings [5]. Group 2 - Medicine Holdings has allegedly used Sinopharm Group's trademarks and business names without authorization, constituting serious infringement, leading Sinopharm Group to initiate legal proceedings [5]. - Sinopharm Group has previously issued multiple statements condemning Medicine Holdings for trademark infringement and other legal disputes, including issues related to unpaid debts [5][7]. - Medicine Holdings has been flagged with multiple negative labels, including operational abnormalities and being a subject of enforcement actions, with no registered employees for 2023 and 2024 [6]. Group 3 - Sinopharm Group is a central enterprise directly managed by the State-owned Assets Supervision and Administration Commission, focusing on life and health, and is a leader in the global industry with over 1,600 subsidiaries [8].